CSPC PHARMA (01093): SYS 6088 Injection (trispecific antibody) receives clinical trial approval in China.

CSPC PHARMA (01093) announced that SYS 6088 Injection (the product), developed by the group, has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. The product is a recombinant humanized trispecific antibody targeting programmed death receptor 1 (PD-1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). It can specifically bind to PD-1 and CTLA-4 on the surface of T cell membranes as well as VEGFA in the tumor microenvironment, thereby reversing T lymphocyte (T cell) exhaustion in the tumor microenvironment, restoring T cell killing function, inhibiting angiogenesis, and promoting T cell activation and expansion during the immune priming phase, exerting a triple synergistic anti-tumor effect. Modification of the Fc region reduces the toxicity risk of the product while effectively extending its half-life. The approved clinical indication for this trial is the treatment of advanced/metastatic solid tumors. Preclinical studies show that the product has a broad range of indications, demonstrating significant anti-tumor effects and good safety across multiple malignant tumor models, and holds high clinical development value.